Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 38

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 38
---
 discussed
below for approximately $19.0 million in net proceeds.

On
May 15, 2024, the Company filed with the SEC a shelf registration statement on Form S-3 (the “2024 Registration Statement”)
for the offer and sale of up to $75 million of its securities. The 2024 Registration Statement was declared effective on May 22, 2024.
The 2024 Registration Statement is intended to provide the Company with flexibility to raise capital in the future for general corporate
purposes. As noted in the prospectus supplement that the Company filed on July 22, 2025, the aggregate market value of our outstanding
Common Stock held by non-affiliates was approximately $79,075,969, based on 2,121,895 shares of Common Stock outstanding as of July
22, 2025, of which 2,100,291 shares were held by non-affiliates, and a price of $37.65 per share, which was the last reported sale price
of our Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”) on June 2, 2025. As a result, our public float increased above
$75.0 million, and we are no longer subject to the limitations contained in General Instruction I.B.6 of Form S-3. The Company sold 5,932
shares of common stock under the ATM Agreement for net proceeds of $99,506 during 2024. The Company sold 551,265 shares of common stock
under the ATM Agreement for net proceeds of $3,638.767 through September 2025. The Company sold 725,346 shares of common stock under the ATM Agreement for
net proceeds of $4,454.797 through November 10, 2025.

May
2025 Offering

On
May 23, 2025, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors, for the issuance
and sale in a private placement of: (i) 185,186 shares of the Company’s common stock, (ii) 296,297 of pre-funded warrants at an
exercise price of $0.0015 per share and (iii) 962,964 warrants at an exercise price of $6.75 per share for gross proceeds of approximately
$3.3 million before the deduction of placement agent fees and offering expenses.

The
Prefunded Warrants became exercisable immediately after issuance for a term of